MYL2

Across TCGA pan-cancer cohorts, MYL2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYL2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MYL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD and HNSC are the cancer types where MYL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.099	0.588	.047	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYL2–LUAD (DFS)

Open the LUAD breakdown →